Press Release
2
 Minute read

VedaBio Appoints Randy Rasmussen, Former CEO of BioFire Diagnostics, to Board of Directors

Published on
October 1, 2024
Contributors
No items found.
Subscribe for updates.
Subscribe
By subscribing, you agree to our Privacy Policy.
Thank you! We've received your submission.
Oops! Something went wrong while submitting the form.
Share

SAN DIEGO--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company at the forefront of molecular detection, today announced the appointment of Randy Rasmussen, Ph.D., to its Board of Directors. Dr. Rasmussen, a visionary in the molecular diagnostics field with over 30 years of experience, brings deep industry knowledge to VedaBio as the company advances its breakthrough platform and enters the crucial stage of product development. In addition to his board position, Dr. Rasmussen will also serve as an Advisor to the company.

"We are honored to welcome Randy to our Board," said Frédéric Sweeney, Ph.D., President and CEO of VedaBio. "Having worked with Randy in the past, I know firsthand the depth of his expertise and strategic insight. His leadership in molecular diagnostics and ability to scale innovation into commercial success make him an invaluable partner as we move into the next phase of our journey."

Dr. Rasmussen co-founded Idaho Technology, later rebranded as BioFire Diagnostics, where he held the roles of President, COO, and ultimately CEO. Under his leadership, BioFire Diagnostics became a transformative force in molecular diagnostics, particularly with its pioneering approach to syndromic testing for infectious diseases. During his tenure, the company grew to over 3,000 employees and exceeded $1 billion in revenue. BioFire was acquired by bioMérieux in 2013, where Dr. Rasmussen served as CEO of the subsidiary until his retirement in 2020. He holds a Bachelor of Science in Biochemistry from Utah State University and a Ph.D. in Molecular Biology from the University of Utah.

"I am thrilled to join VedaBio at such a pivotal time," said Dr. Rasmussen. "The company's technology and product-focused vision hold immense promise to reshape the future of molecular detection. I look forward to working alongside Fred and the talented team to drive VedaBio’s innovative platform to market and help realize its full potential."

About CRISPR Cascade

VedaBio’s CRISPR Cascade is a disruptive new molecular detection platform that operates with a combination of speed, accuracy and simplicity. The CRISPR Cascade platform eliminates the need for target amplification while maintaining high accuracy, all with a rapid analytical turnaround time. Unlike PCR or other DNA/RNA amplification technologies where assay design complexity significantly increases with multiplexing, the CRISPR Cascade removes several fundamental constraints, enabling incredibly simple, highly multiplexed assays without signal loss or cross reactivity issues, for example. With performance that combines highly sensitive, accurate and rapid results, the CRISPR Cascade unlocks a universe of possibilities.

About VedaBio

VedaBio is revolutionizing molecular biology with its breakthrough platform for ultra-rapid molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. Our CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries. Learn more at vedabio.com.

Contacts

Karen Sharma
CG Life
[email protected]

Articles

Discover More Press

Explore our latest articles for valuable insights.

Press Release
5 min read

VedaBio Appoints Dr. G. Brett Robb as Senior Scientific Director and Head of CRISPR Science

SAN DIEGO, Calif., September 4, 2024 – VedaBio, a biotechnology company leading a paradigm shift in molecular detection, today announced the appointment of G. Brett Robb, Ph.D., as Senior Scientific Director and Head of CRISPR Science. With over...
Press Release
5 min read

VedaBio Launches with Over $40 Million to Revolutionize Molecular Detection

Unveils breakthrough CRISPR CascadeTM platform. Platform delivers best-in-class accuracy without need for target amplification, resulting in analytical turnaround time of < 1 minute and massive multiplexing capabilities. Company’s leadership...
Press Release
5 min read

VedaBio Strengthens Management Team

VedaBio, the biotechnology company leading a paradigm-shift in molecular detection, today announced that Frédéric Sweeney, PhD, has been appointed President and Chief Executive Officer.